Press releases

WINNIPEG, Manitoba (January 27, 2004) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms, is pleased to announce the appointment of Dr. Geoffrey Grant to its Board of Directors. Dr. Grant brings thirty years of pertinent industry and academic experience to the board.

“We are justifiably excited to welcome Dr. Geoffrey Grant to our Board of Directors,” stated Dr. Albert Friesen, Chairman of Kane Biotech. “Given his years of experience in both research technology commercialization and biotech company management, Dr. Grant will be a tremendous asset to the Board.”

About Dr. Geoffrey Grant
Dr. Grant is currently the Director of the Arlington Technology Incubator (ATI) at the University of Texas. Previous to joining the ATI, Dr. Grant spent five years as the Senior Manager of Research and Technology at the University of North Texas Health Science Center at Fort Worth, where he led and managed all aspects of technology commercialization and intellectual property protection.

From 1991 until 1993, Dr. Grant served with Micrologix Biotech Inc. (formerly Microtek). During his time as CEO for Micrologix, he oversaw the transition from a privately held entity to a publicly traded company. Following his experience at Micrologix, Dr. Grant served as an independent biotech industry consultant in California until joining the University of
North Texas Health Science Center at Fort Worth in 1998.

Dr. Grant began his career as a researcher, serving at the Salk Institute of Biological Studies in San Diego, California as a part of the Neuroendocrinology Group. In addition to authoring numerous publications, grants and patents, Dr. Grant was the co-discoverer of Somatostatin, which became the first genetically engineered peptide made commercially available. Somatostatin was commercialized by Genentech Inc.

Dr. Grant received his B.Sc. and M.Sc. from the University of British Columbia and Ph.D. in Genetics and Cell Biology from the University of California - San Diego.

About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms are microbial populations in a self-produced matrix able to withstand high temperatures, host immune responses and antibiotics. An estimated 65% of all human infections involve biofilms.

-30-

For more information, please contact:

Marcus Enns
President
Kane Biotech Inc.
204-487-2328 phone
204-488-9823 fax
info@kanebiotech.com
www.kanebiotech.com

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. This release is not to be construed as an offer to sell, or a solicitation for an offer to buy or trade securities.